Navigation Links
Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
Date:11/10/2010

THOUSAND OAKS, Calif., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients. Data also showed that patients receiving SOC therapies required splenectomies earlier when compared with patients treated with Nplate. Additionally, patients in the Nplate group experienced increased platelet counts, higher platelet response rates, less bleeding, and fewer blood transfusions compared to patients in the SOC group. Adverse events associated with Nplate treatment were similar to those in previous studies, were generally mild or moderate in severity, and did not result in treatment discontinuation. Headache and fatigue were the most commonly reported adverse events.

"This is the first study to compare a variety of ITP treatments and demonstrated that Nplate not only maintained platelet counts more effectively than standard medical treatments, but also reduced overall treatment failure and splenectomies," said Dr. David J. Kuter, head of Hematology, Massachusetts General Hospital, Boston, and lead investigator and study author.

Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events.

Nplate Study Meets Co-Primary Endpoints

The year-long, open-label study had two co-primary endpoints: the incidence of treatment failure and the incidence of splenectomy.


    SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
    2. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
    3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
    4. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
    5. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
    6. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
    7. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
    8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
    9. Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
    10. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
    11. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Sept. 17, 2014   OTEMR, Inc. , ONETOUCH ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  ONETOUCH EMR 2.0 was certified on July 14, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
    (Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer from ... disease. Recently the FDA approved the launch ... an innovative implant device developed by Spinal Kinetics, which may ... neck and or arm pain. Hospital for Special Surgery (HSS), ... only hospital in New York City ...
    (Date:9/17/2014)... Calif. , Sept. 17, 2014   ... data analytics solution that brings complete visibility to ... risks in an ever-evolving reimbursement landscape. Powered by ... brings transparency to the critical point between patient ... impact revenue. The solution will improve revenue capture, ...
    Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
    ... SPRING, Md., Nov. 23, 2011 The FDA today ... owner for substituting ingredients and products without noting the ... filed on behalf of the FDA by the U.S. ... and distributing more than 400 products for being in ...
    ... 23, 2011 /PRNewswire-iReach/ -- Now in its 13th ... discuss, investigate, and learn about the latest in pharmaceutical technology. ... at the Crocus Expo, International Exhibition Centre, in Moscow. ... sustainable air filters — a key ...
    Cached Medicine Technology:FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 2FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 3Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 2Camfil Farr to Discuss Sustainable Air Filtration at PHARMTECH 2011 3
    (Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
    (Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
    (Date:9/17/2014)... New York (PRWEB) September 17, 2014 ... involving the Conserve line of metal-on-metal hip replacements ... underway in U.S. District Court, Northern District of ... updated Case List issued by the U.S. Judicial ... at least 397 product liability claims have been ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
    (Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
    Breaking Medicine News(10 mins):Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
    ... Month, BETHESDA, Md., Jan. 3 AABB (formerly ... individuals,participating in the presidential elections to continue making an ... the month of,January, National Blood Donor Month (NBDM) provides ... give blood at a time of the year when,it ...
    ... ... Refractory Patients to Replace Current TIME-2 ... Trial ... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today announced that the Tanespimycin in,Myeloma Evaluation or TIME-1 pivotal Phase ...
    ... young people,s blood sugar levels, study finds , THURSDAY, Jan. ... three nights running has the same negative effect on the ... pounds, diabetes researchers report. , In fact, young adults ... their risk of type 2 diabetes, according to a study ...
    ... others with a family history of ... glaucoma are particularly vulnerable, SAN FRANCISCO, Jan. 3 ... do not notice as their peripheral,vision diminishes or blind spots occur. ... disease are unaware of their condition.,January is Glaucoma Awareness Month, and ...
    ... Abbott (NYSE: ABT ),will announce its financial results ... on Wednesday, Jan. 23, 2008, before the market opens., ... webcast of the earnings,conference call at 8 a.m. Central ... Investor Relations Web site at, http://www.abbottinvestor.com . An archived ...
    ... the story is the same: New,Year,s resolutions made, New ... be combined with online health tools and expert advice,to ... growing health,properties on the Internet -- launched "Resolutions 2.0," ... video from Revolution Health at:, http://media.medialink.com/WebNR.aspx?story=34279 ) "Resolutions ...
    Cached Medicine News:Health News:Exercise Your Right to Vote and Continue to Make a Difference by Giving Blood in 2008 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 2Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 3Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 4Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 5Health News:Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma 6Health News:Lack of Deep Sleep Raises Diabetes Risk 2Health News:Lack of Deep Sleep Raises Diabetes Risk 3Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:VIDEO from Medialink and Revolution Health: RevolutionHealth.com Launches 'Resolutions 2.0' 2
    ... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
    ... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
    The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
    The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
    Medicine Products: